<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="34155">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02661958</url>
  </required_header>
  <id_info>
    <org_study_id>SGT-65-02</org_study_id>
    <nct_id>NCT02661958</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety, and Tolerability of S6G5T-1 and S6G5T-3 for the Treatment of Acne Vulgaris</brief_title>
  <official_title>A Phase 2, Randomized, Multicenter, Double-Blind, Active and Vehicle Controlled Parallel-group Study Evaluating the Efficacy, Safety, and Tolerability of Products S6G5T-3 and S6G5T-1 for the Treatment of Acne Vulgaris for 12 Weeks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sol-Gel Technologies, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Accelovance</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sol-Gel Technologies, Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the superiority in efficacy and assess safety and
      tolerability of the products S6G5T-3 and S6G5T-1 as compared to their respective active
      components or the vehicle for the treatment of acne.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Investigator's Global Assessment (IGA)</measure>
    <time_frame>week 12</time_frame>
    <description>Proportion of subjects with an assessment of clear or almost clear with at least a 2-grade improvement in IGA at Week 12</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute change in lesion count (separately for inflammatory and non-inflammatory)</measure>
    <time_frame>baseline and week 12</time_frame>
    <description>Absolute change from Baseline in lesion count on the face at Week 12 (separately for inflammatory and non-inflammatory lesions)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage change from Baseline in lesion count on the face at Week 12</measure>
    <time_frame>Baseline and week 12</time_frame>
    <description>Percentage change from Baseline in lesion count on the face at Week 12 (separately for inflammatory and non-inflammatory lesions)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assessments of IGA at each time point</measure>
    <time_frame>baseline, week 4, 8</time_frame>
    <description>Supportive efficacy variables are the assessments of IGA percentage change at each time point during the treatment period, namely at Weeks 4, and 8.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">660</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>S6G5T-3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>topical cream</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S6G5T-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>topical cream</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S6G5T-5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>topical cream</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S6G5T-7</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>topical cream</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S6G5T-6</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>topical cream</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S6G5T-8</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>topical cream</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S6G5T-3</intervention_name>
    <description>once a day topical cream</description>
    <arm_group_label>S6G5T-3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S6G5T-1</intervention_name>
    <description>once a day topical cream</description>
    <arm_group_label>S6G5T-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S6G5T-5</intervention_name>
    <description>once a day topical cream</description>
    <arm_group_label>S6G5T-5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S6G5T-6</intervention_name>
    <description>once a day topical cream</description>
    <arm_group_label>S6G5T-6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S6G5T-7</intervention_name>
    <description>once a day topical cream</description>
    <arm_group_label>S6G5T-7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S6G5T-8</intervention_name>
    <description>once a day topical cream</description>
    <arm_group_label>S6G5T-8</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female subjects 9 years of age or older.

          2. In good general health Based on medical records

          3. Have a diagnosis of facial acne with &gt;25 and &lt;100 non-inflammatory lesions and &gt;20
             and &lt;50 inflammatory lesions.

          4. Have a score of &quot;3&quot; or &quot;4&quot; (Moderate or Severe) on the IGA scale.

          5. Have two or fewer cysts or nodules (defined as an inflammatory lesion greater than or
             equal to 5 mm in diameter).

          6. Sexually active women of child-bearing potential must use one of the following birth
             control options:

             One of these highly effective contraception methods:

             i. Intrauterine device (IUD); ii. Hormonal, for at least 3 months (Pills, injections,
             implants, transdermal patch, vaginal ring); iii. Tubal ligation; iv. Partner
             vasectomy,

          7. OR A barrier form of contraception (listed below) i. Male or female condom; ii.
             Diaphragm with spermicides; iii. Cervical cap with spermicides; iv. Contraceptive
             sponge

          8. Willingness and capacity for protocol compliance (for subjects under the age of
             consent, the parent/guardian must be willing and able to comply with study
             requirements).

          9. Male subjects must be clean-shaven and agree to remain so for during the study
             visits.

         10. Consent to participate, verified by signing an approved written Informed Consent Form
             and HIPAA; for subjects under the age of consent, both a signed assent form and a
             signed Informed Consent Form from the parent/guardian are required in accordance with
             local and federal regulations.

        Exclusion Criteria:

          1. More than two acne nodules or cysts (defined as an inflammatory lesion greater than
             or equal to 5 mm in diameter)

          2. Acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne, etc or
             severe acne requiring systemic treatment.

          3. Underlying disease that requires the use of interfering topical or systemic therapy.

          4. Other dermatological conditions that require the use of interfering topical or
             systemic therapy or that might interfere with study assessments such as, but not
             limited to, atopic dermatitis, perioral dermatitis, or rosacea.

          5. Beard, facial hair, or tattoo that may interfere with study assessments.

          6. Use of tanning booths or tanning lamps within one week prior to Baseline and an
             unwillingness to refrain from use during the study.

          7. Use of hormonal contraceptives, unless subject is on a stable dose for at least three
             months prior to enrollment.

          8. Use of hormonal contraceptives solely for the control of acne.

          9. Use of prohibited medications prior to the study and unwillingness to refrain from
             use during the study.

         10. Known sensitivities to the study drug ingredients. Allergy to benzoyl peroxide,
             tretinoin, parabens and glycerin or other ingredients listed in the investigator
             brochure.

         11. Clinically significant abnormal findings or conditions (other than acne), which
             might, in the opinion of the investigator, interfere with study evaluations or pose a
             risk to subject safety during the study.

         12. Female subjects who are pregnant and/or nursing or planning to become pregnant during
             the course of the trial. Subjects who test positive for pregnancy after start of test
             treatment will be discontinued from test treatment but will be followed for safety
             purposes.

         13. Participation in another investigational drug or device research study within 30 days
             of enrollment or five half-lives of the drug, whichever is longer.

         14. Current or history of facial skin cancer.

         15. Is an employee or family member of the study investigator or other study staff having
             direct involvement in the proposed study.

         16. Is a family member of a study participant recruited and enrolled into the proposed
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Piyush Sheladia, M.S.</last_name>
    <role>Study Chair</role>
    <affiliation>Accelovance</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ofra Levy-Hacham, Ph.D</last_name>
    <phone>+972733729453</phone>
    <email>ofra.levy-hacham@sol-gel.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ofer Toledano, Ph.D</last_name>
    <phone>+972733729452</phone>
    <email>ofer.toledano@sol-gel.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Orange County Research Institute</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvia De Veyra</last_name>
      <phone>714-635-7100</phone>
      <email>SDEVEYRA@OCRI.US</email>
    </contact>
    <investigator>
      <last_name>Steve Sitar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>eStudySite</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosalynn Landazuri</last_name>
      <phone>619-955-5246</phone>
      <email>rlandazuri@estudysite.com</email>
    </contact>
    <investigator>
      <last_name>Scott Overcash, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>T. Joseph Raoof MD, Inc./Encino Research Center</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91436</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Associates</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen Iben</last_name>
      <phone>310-337-7171</phone>
      <email>ciben@drsofen.com</email>
    </contact>
    <investigator>
      <last_name>Howard Sofen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>eStudySite</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markita Helm, CCRP</last_name>
      <phone>760-631-3056</phone>
      <email>MHelm@estudysite.com</email>
    </contact>
    <investigator>
      <last_name>Paul Manos, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Empire Clinical Research</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah J ordan-Gordon</last_name>
      <phone>909-981-5321</phone>
      <email>sgordon@empireclinicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Yogesh K Paliwal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Horizons Clinical Research Center, LLC</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel Arnold, RN, BSN, CCRC</last_name>
      <phone>303-399-4067</phone>
      <phone_ext>11</phone_ext>
      <email>iarnold@horizonscrc.com</email>
    </contact>
    <investigator>
      <last_name>Nancy Krywonis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MOORE Clinical Research, Inc</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Werner</last_name>
      <phone>813-948-7550</phone>
      <email>cwerner@moorecr.com</email>
    </contact>
    <investigator>
      <last_name>Susan M Barker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Health Awareness, Inc.</name>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <zip>33458</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Smorall</last_name>
      <phone>561-741-2033</phone>
      <email>laura@healthawarenessinc.com</email>
    </contact>
    <investigator>
      <last_name>Ronald Z Surowitz, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LCC Medical Research Institute, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivia Falcon Valdes</last_name>
      <phone>305-400-0814</phone>
      <email>ofalconcrc@lccmedicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Yamirka Duardo Guerra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oceane7 Clinical Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joel Rodriguez</last_name>
      <phone>305-261-2738</phone>
      <email>j.rodriguez@oceane7.us</email>
    </contact>
    <investigator>
      <last_name>John L Cosby, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>RM Medical Research, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis E Sanchez</last_name>
      <phone>954-243-1181</phone>
      <email>lsanchez@rmmedicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Marta Delgado, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IMIC Inc.</name>
      <address>
        <city>Palmetto Bay</city>
        <state>Florida</state>
        <zip>33157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loyda C Espinoza, CCRP</last_name>
      <phone>786-310-7477</phone>
      <email>loyda@aktamedika.com</email>
    </contact>
    <investigator>
      <last_name>Ramon Guevara, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Trials of Florida, Inc.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Cammacho</last_name>
      <phone>813-873-8102</phone>
      <email>Nicole@crtfi.com</email>
    </contact>
    <investigator>
      <last_name>Sady A Alpizar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33634</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Medina</last_name>
      <phone>813-877-8839</phone>
      <email>amedina@meridienresearch.net</email>
    </contact>
    <investigator>
      <last_name>Cynthia Huffman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates, LLC</name>
      <address>
        <city>Augusta</city>
        <state>Kansas</state>
        <zip>67010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dorothy Wilson</last_name>
      <phone>316-260-8822</phone>
      <email>dwilson@heartlandresearch.com</email>
    </contact>
    <investigator>
      <last_name>Michael A Rausch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dermatology Specialists Research</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon Gabbard, MSN, RN</last_name>
      <phone>502-585-9059</phone>
      <phone_ext>155</phone_ext>
      <email>sgabbard@dsrtrials.com</email>
    </contact>
    <investigator>
      <last_name>Joseph F Fowler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DermResearch, PLLC</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40217</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Stewart</last_name>
      <phone>502-451-9000</phone>
      <email>wedoderm@yahoo.com</email>
    </contact>
    <contact_backup>
      <email>wedoderm@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Leon Kircik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Core Healthcare Group</name>
      <address>
        <city>Cerritos</city>
        <state>Louisiana</state>
        <zip>90703</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mayracezl Rodriguez</last_name>
      <phone>562-924-8880</phone>
      <email>mrodriguezchg@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Francisco Badar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DelRicht Research</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Hastings</last_name>
      <phone>504-336-2667</phone>
      <email>rhastings@delricht.com</email>
    </contact>
    <investigator>
      <last_name>Sarah Jackson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MediSearch clinical Trials</name>
      <address>
        <city>St. Joseph</city>
        <state>Missouri</state>
        <zip>64506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melody Lynn Stone, MD, FAAD</last_name>
      <phone>9132261124</phone>
      <email>mlsmedisearch@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Amy Lean Horner, PA-C</last_name>
      <phone>9132261124</phone>
      <email>mlsmedisearch@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Quality Clinical Research Inc.</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Kalili</last_name>
      <phone>402-934-0044</phone>
      <email>NKalili@qcromaha.com</email>
    </contact>
    <investigator>
      <last_name>Michael Dunn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>eStudySite</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew O'Sullivan</last_name>
      <phone>702-410-2970</phone>
      <email>mosullivan@estudysite.com</email>
    </contact>
    <investigator>
      <last_name>Elliot Shin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ActivMed Practices and Research, Inc.</name>
      <address>
        <city>Portsmouth</city>
        <state>New Hampshire</state>
        <zip>3801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha Lemovitz</last_name>
      <phone>603-319-8863</phone>
      <email>slemovitz@activmedresearch.com</email>
    </contact>
    <investigator>
      <last_name>Abel Jarell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Clinical Trials</name>
      <address>
        <city>Manhattan</city>
        <state>New York</state>
        <zip>10018</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karina Betances</last_name>
      <phone>646-625-3011</phone>
      <email>karina@nycclinicaltrials.com</email>
    </contact>
    <investigator>
      <last_name>Scott Bloom, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Derm Research Center of New York, Inc</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11790</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Courtenay Dipietro</last_name>
      <phone>631-689-1900</phone>
      <email>mrubesamen@drcny.com</email>
    </contact>
    <contact_backup>
      <email>cdipietro@drcny.com</email>
    </contact_backup>
    <investigator>
      <last_name>Elyse Rafal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dermatology Consulting Services</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vicky Ellis</last_name>
      <phone>336-841-3865</phone>
      <email>dcs3@northstate.net</email>
    </contact>
    <investigator>
      <last_name>Zoe Diana Draelos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates, LLC</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruby Lancaster</last_name>
      <phone>919-781-2514</phone>
      <email>rlancaster@wakeresearch.com</email>
    </contact>
    <investigator>
      <last_name>Adnan Nasir, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Paddington Testing Co, Inc</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hirak B Routh</last_name>
      <phone>215-563-7330</phone>
      <email>hirakbrouth@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Jennifer C Parish, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Palmetto Clinical Trial Services, LLC @ Greenville Dermatology</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Starsha R Cantor</last_name>
      <phone>864-351-9632</phone>
      <email>scantor@palmettoclinical.com</email>
    </contact>
    <investigator>
      <last_name>Matthew Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Discover Research, Inc.</name>
      <address>
        <city>Bryan</city>
        <state>Texas</state>
        <zip>77802</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karla A. Hall</last_name>
      <phone>979-731-1212</phone>
      <email>khall@dribcs.com</email>
    </contact>
    <investigator>
      <last_name>Anna P Damian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Houston Clinical Research Services LLC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77055</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Bula</last_name>
      <phone>281-738-2642</phone>
      <email>lbula@whcrs.com</email>
    </contact>
    <investigator>
      <last_name>Oscar De Valle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Austin Institute for Clinical Research, Inc.</name>
      <address>
        <city>Pflugerville</city>
        <state>Texas</state>
        <zip>78660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Beanblossom</last_name>
      <phone>512-279-2545</phone>
      <email>Jennifer@atxresearch.com</email>
    </contact>
    <investigator>
      <last_name>Edward L Lain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Dermatology and Laser Specialists</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeannette Woodworth</last_name>
      <phone>210-852-2779</phone>
      <email>jeannette@texasdls.com</email>
    </contact>
    <investigator>
      <last_name>Emily M Becker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 19, 2016</lastchanged_date>
  <firstreceived_date>January 11, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acne vulgaris</keyword>
  <keyword>acne</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
